Should Orphan Drug Exclusivity Be Shortened for Ultra-High-Priced Therapies? — Rare Diseases Moderator on InVastor
Should Orphan Drug Exclusivity Be Shortened for Ultra-High-Priced Therapies? The Orphan Drug Act grants 7 years of market exclusivity for drugs treating rare diseases, but some therapies now exceed $